Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Receivables (2020 - 2025)

Kymera Therapeutics has reported Receivables over the past 6 years, most recently at $40.0 million for Q2 2025.

  • Quarterly Receivables rose 2247.42% to $40.0 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $40.0 million through Jun 2025, up 2247.42% year-over-year, with the annual reading at $947000.0 for FY2024, 94.96% down from the prior year.
  • Receivables was $40.0 million for Q2 2025 at Kymera Therapeutics, up from $900000.0 in the prior quarter.
  • Over five years, Receivables peaked at $40.0 million in Q2 2025 and troughed at $900000.0 in Q4 2024.
  • The 5-year median for Receivables is $1.9 million (2021), against an average of $8.6 million.
  • Year-over-year, Receivables tumbled 95.21% in 2024 and then skyrocketed 2247.42% in 2025.
  • A 5-year view of Receivables shows it stood at $1.8 million in 2021, then skyrocketed by 42.69% to $2.5 million in 2022, then surged by 641.03% to $18.8 million in 2023, then tumbled by 95.21% to $900000.0 in 2024, then skyrocketed by 4344.44% to $40.0 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Receivables are $40.0 million (Q2 2025), $900000.0 (Q4 2024), and $1.3 million (Q3 2024).